Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5524815 | 0.92 | CHRM3 (0.60) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5575975 | 0.92 | CHRM3 (0.60) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5524818 | 0.90 | CHRM3 (0.57) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5520338 | 0.86 | CHRM3 (0.54) | CHRM3CHRM1AURKA | |
| SCHEMBL14435012 | 0.84 | CHRM3 (0.68) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5575936 | 0.83 | CHRM3 (0.85) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5525860 | 0.83 | CHRM3 (0.85) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5525864 | 0.81 | CHRM3 (0.81) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5525503 | 0.81 | CHRM3 (0.64) | CHRM3CHRM1MEN1LMNAMAPK1 | |
| Trifluoroacetic Acid SCHEMBL5525505 | 0.79 | CHRM3 (0.62) | CHRM3CHRM1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | claimed |
| EP-1751089-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | claimed |
| WO-2005086873-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (US) | 2005-09-22 | — | — | WO | claimed |
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| EP-1751089-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005086873-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM1 8/4885MEN1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.